SCHEMBL4928566

SCHEMBL4928566

C=CCNCCCCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
ABCC4 O15439 1/20 0.52
TSHR P16473 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PRMT1 Q99873 1/20 0.47
LMNA P02545 3/20 0.46
NFKB1 P19838 1/20 0.44
PMP22 Q01453 1/20 0.44
ADRA1A P35348 1/20 0.44
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.40
MAPK1 P28482 1/20 0.39
FAAH O00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3160520 0.98 MAPT (0.55) MAPTABCC4TSHRSMN1; SMN2PRMT1
SCHEMBL254214 0.98 MAPT (0.55) MAPTABCC4TSHRSMN1; SMN2PRMT1
SCHEMBL614518 0.94 MAPT (0.48) MAPTABCC4TSHRSMN1; SMN2PRMT1
Adipic Acid SCHEMBL27737322 0.89 MAPT (0.58) MAPTABCC4TSHRSMN1; SMN2PRMT1
Adipic Acid SCHEMBL7106709 0.89 NFKB1 (0.52) MAPTABCC4TSHRSMN1; SMN2PRMT1
SCHEMBL4616389 0.86 MAPT (0.41) MAPTABCC4TSHRSMN1; SMN2LMNA
SCHEMBL253528 0.85
SCHEMBL3435875 0.83 MAPT (0.42) MAPTABCC4TSHRSMN1; SMN2LMNA
SCHEMBL8856051 0.82 KDM4E (0.43) MAPTABCC4TSHRSMN1; SMN2LMNA
SCHEMBL16340122 0.81 KDM4E (0.42) MAPTABCC4TSHRSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof SIENA BIOTECH S.P.A. (IT) 2008-11-06 US disclosed
EP-1778658-A2 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF Siena Biotech S.p.A. (IT) 2007-05-02 EP disclosed
WO-2006008133-A2 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF SIENA BIOTECH S.P.A. (IT) 2006-01-26 WO disclosed
EP-0277624-A2 A composition comprising the addition product of a vinyl sulfone dye and a secondary amine and process for dyeing a polyamide therewith HOECHST CELANESE CORPORATION (US) 1988-08-10 EP disclosed
US-4762524-A Composition comprising the addition product of a vinyl-sulfone dye and a secondary amine and process for dyeing a polyamide therewith HOECHST CELANESE CORPORATION (US) 1988-08-09 US disclosed
US-4082792-A SECONDARY ALKYL PRIMARY AMINE, ALKENOIC ACID, PRIMARY OR SECONDARY ALCOHOL TEXACO INC. (US) 1978-04-04 US disclosed
US-3976682-A ALKYLAMMONIUM ALKYLAMINOALKANOATES, FREEZE-THAW ADDITIVE, CORROSION INHIBITOR, PIGMENT GRINDING TEXACO INC. (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof CHRNA7, CHRNA5, CHRNA1 MAPT 545/4885ABCC4 2398/4885TSHR 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.